Velocardiofacial (VCFS; 22q11.2; DiGeorge) Syndrome Study
DiGeorge Syndrome, Velocardiofacial Syndrome, 22q11.2 Syndrome
About this trial
This is an observational trial for DiGeorge Syndrome focused on measuring Velocardiofacial Syndrome, Susceptibility Genes, Neuroimaging, 22q11.2, Psychosis, Mircodeletion, DiGeorge Syndrome, 22q11.2 Syndrome
Eligibility Criteria
INCLUSION CRITERIA: Only adults between age 18 and 50 will be studied. 22q11.2 participants: 22q11.2 deletion will be confirmed by FISH. IQ (WAIS). In phase 1: IQ in the general range of the population (greater than 85) as ascertained using the 2- and 4-subset forms of the Wechsler Abbreviated Scale of Intelligence (Wechsler, 1999). Informed consent. EXCLUSION CRITERIA: (Phase 1 only) Any lifetime diagnosis of schizophrenia, schizoaffective disorder, or schizotypal disorder and/or current pychotropic medication or any neuroleptic medication in the previous year. (all phases) Chronological age greater 50 years. Contraindication of MRI scanning (ferromagnetic metal implanted in body, prostheses containing such metal, pacemaker devices). Pregnancy. Medication affecting central nervous function. Severe somatic disorders precluding travel to the clinical center or participation in imaging procedures. Hypothyroidism not compensated by medication. Neurological disorders excluding those of exclusively peripheral location.
Sites / Locations
- National Institutes of Health Clinical Center, 9000 Rockville Pike